| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human IL23 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是关于IL-23抗体的3篇关键文献及其摘要，涵盖临床应用与机制研究：
---
1. **文献名称**：*Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)*
**作者**：Papp, K. et al.
**摘要**：该III期临床试验显示，IL-12/23单抗优特克单抗(Ustekinumab)在中重度银屑病患者中显著改善皮损，且长期安全性良好，支持其作为慢性疾病管理的有效疗法。
2. **文献名称**：*Guselkumab versus adalimumab for the treatment of moderate-to-severe psoriasis: Results from the VOYAGE 1 trial*
**作者**：Reich, K. et al.
**摘要**：研究对比IL-23p19单抗古塞库单抗(Guselkumab)与TNF抑制剂阿达木单抗的疗效，发现古塞库单抗在银屑病皮损清除率及持续缓解方面更具优势，凸显IL-23靶向治疗的高效性。
3. **文献名称**：*Risankizumab in patients with moderate-to-severe Crohn's disease: Results from the ADVANCE and MOTIVATE trials*
**作者**：Feagan, B.G. et al.
**摘要**：两项III期试验表明，IL-23p19单抗利生奇珠单抗(Risankizumab)可显著诱导中重度克罗恩病患者临床缓解，验证IL-23通路在肠道炎症中的核心作用。
---
**补充机制研究**：
4. **文献名称**：*The IL-23/Th17 axis in the immunopathogenesis of psoriasis*
**作者**：Gaffen, S.L. & Jain, R.
**摘要**：综述系统阐述IL-23通过激活Th17细胞驱动银屑病等自身免疫疾病的机制，为抗体类药物开发提供理论基础。
---
以上文献聚焦IL-23抗体在银屑病、克罗恩病的临床突破及分子机制，覆盖关键药物与核心研究进展。
Interleukin-23 (IL-23) is a pro-inflammatory cytokine belonging to the IL-12 family, primarily produced by activated dendritic cells and macrophages. It plays a pivotal role in chronic inflammation and autoimmune diseases by promoting the differentiation and maintenance of T helper 17 (Th17) cells, which secrete inflammatory cytokines like IL-17 and IL-22. Dysregulated IL-23 signaling is implicated in conditions such as psoriasis, inflammatory bowel disease (IBD), and psoriatic arthritis.
IL-23 antibodies are biologic therapies designed to block this pathway. These monoclonal antibodies target either the IL-23-specific p19 subunit or the shared p40 subunit of IL-23 and IL-12. Early agents like ustekinumab (anti-p40) showed efficacy but lacked specificity. Newer antibodies, such as risankizumab, guselkumab, and tildrakizumab, selectively inhibit IL-23 by binding to p19. minimizing off-target effects. By neutralizing IL-23. these antibodies disrupt Th17-mediated inflammation, reducing disease activity.
Approved for moderate-to-severe plaque psoriasis and undergoing trials for IBD, IL-23 inhibitors offer improved safety profiles compared to broader immunosuppressants. Their development reflects a shift toward targeted immunomodulation, emphasizing precision in treating autoimmune disorders. Research continues to explore their potential in other IL-23-driven conditions, solidifying their role as transformative therapies in autoimmune care.
×
